V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008160 | 240005007 | null | 89 | null | null | 2016-04-19 | Cisplatin + Etoposide (3 day) | N | N | 240002416 | TRASTUZUMAB |
| 240008161 | 240010772 | null | 70.7 | null | null | 2015-08-06 | CISPLATIN + GEMCITABINE | 1 | Y | 240002455 | ABVD |
| 240008162 | 240005008 | 1.71 | 77.6 | null | null | 2017-12-06 | CVP | 99 | null | 240002461 | CYCLOPHOSPHAMIDE |
| 240008163 | 240005009 | 1.73 | null | Curative (C) | 2014-01-07 | 2014-01-10 | Oxaliplatin + Modified de Gramont | 2 | null | 240002469 | AML18 TRIAL |
| 240008164 | 240010773 | 1.65 | 83 | Disease modification (D) | 2017-10-02 | 2017-10-11 | REMODLB TRIAL | N | N | 240002470 | CAPECITABINE + CISPLATIN |
| 240008165 | 240010773 | 1.7 | 100 | Palliative (P) | 2014-11-21 | 2014-11-24 | Erlotinib | 02 | N | 240002470 | ABVD |
| 240008166 | 240005010 | 1.76 | 82.6 | Palliative (P) | null | 2015-09-28 | PMitCEBO-R | null | null | 240002502 | CYCLOPHOSPHAMIDE |
| 240008167 | 240005011 | 1.67 | 0 | Curative (C) | 2014-12-24 | 2015-01-08 | EP | N | N | 240002584 | LENALIDOMIDE |
| 240008168 | 240005012 | 1.63 | 67.7 | Curative (C) | 2013-08-26 | 2013-08-27 | ABVD | N | N | 240002594 | MATRIX TRIAL |
| 240008169 | 240005012 | 1.71 | 0 | Palliative (P) | 2016-11-17 | 2016-11-24 | Docetaxel + Gemcitabine with GCSF | 02 | N | 240002594 | GEMCITABINE |
| 240008170 | 240005012 | 1.54 | 50 | Palliative (P) | 2016-05-25 | 2016-05-26 | ABVD | 02 | N | 240002594 | R-EPOCH |
| 240008171 | 240005012 | null | 59 | Palliative (P) | 2017-12-13 | 2018-01-20 | BEP 3 day | N | N | 240002594 | GEMCARBO |
| 240008172 | 240005013 | 1.61 | 55.3 | Palliative (P) | 2017-08-17 | 2017-08-24 | BCG Intravesical | 02 | N | 240002727 | IDARAM |
| 240008173 | 240010775 | 1.57 | 86.8 | null | 2017-11-01 | 2017-11-01 | Cisplatin + Paclitaxel | N | N | 240002765 | BEVACIZUMAB |
| 240008174 | 240005014 | 1.6 | 49.4 | Palliative (P) | 2016-11-30 | 2016-12-08 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | N | N | 240002781 | NORDIC |
| 240008175 | 240005015 | 1.61 | null | null | 2015-11-06 | 2015-11-14 | Docetaxel + Gemcitabine with GCSF | 02 | N | 240002800 | ERLOTINIB |
| 240008176 | 240005015 | 1.47 | 87 | Palliative (P) | 2018-01-27 | 2018-02-24 | Cisplatin + Topotecan | N | null | 240002800 | CISPLATIN + ETOPOSIDE |
| 240008177 | 240005015 | 0 | 73.3 | null | 2018-01-21 | 2018-01-28 | CVP | 2 | N | 240002800 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008178 | 240005016 | 1.8 | 114 | Curative (C) | 2016-05-28 | 2016-06-04 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 240002841 | R-EPOCH |
| 240008179 | 240005017 | 1.81 | null | Curative (C) | 2016-02-08 | 2016-02-08 | CYTARABINE | N | null | 240002854 | GEMCARBO |
| 240008180 | 240005017 | 1.58 | 69.9 | Palliative (P) | 2018-07-03 | 2018-07-13 | Cisplatin + Etoposide (3 day) | 02 | N | 240002854 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE |
| 240008181 | 240005018 | null | 66.3 | Palliative (P) | 2014-06-19 | 2014-06-27 | CVP | N | null | 240002961 | ABVD |
| 240008183 | 240005020 | 1.75 | 103 | Palliative (P) | 2014-07-28 | 2014-08-07 | Methotrexate intrathecal | N | N | 240003031 | ABIRATERONE |
| 240008184 | 240005020 | 1.6 | 65.8 | Palliative (P) | 2017-02-10 | 2017-02-10 | FLAG + Idarubicin | N | N | 240003031 | CAPECITABINE |
| 240008185 | 240005021 | 1.81 | 65.8 | Palliative (P) | 2014-05-03 | 2014-05-29 | Cetuximab 7 day (>Cycle 2) | 02 | N | 240003160 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 240008186 | 240005021 | null | 65.8 | Curative (C) | 2016-10-10 | 2016-10-10 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | N | N | 240003160 | DHAP |
| 240008187 | 240005021 | 1.65 | 68.2 | null | 2017-10-20 | 2017-10-27 | IBRUTINIB | N | N | 240003160 | IVA |
| 240008188 | 240005021 | 1.74 | 67.3 | null | 2016-10-25 | 2016-10-25 | NORDIC | N | N | 240003160 | ECX |
| 240008189 | 240005021 | 1.63 | 54 | Curative (C) | 2016-05-24 | 2016-06-04 | Cisplatin + Topotecan | N | N | 240003160 | BORTEZOMIB + THALIDOMIDE |
| 240008190 | 240005021 | null | null | Curative (C) | null | 2015-08-07 | ABVD | N | null | 240003160 | TRIPLE INTRATHECAL |
| 240008191 | 240005022 | null | null | Curative (C) | 2017-09-17 | 2017-09-18 | BEAM | 99 | null | 240003307 | CYCLOPHOSPHAMIDE |
| 240008192 | 240005022 | 1.61 | 80.8 | Palliative (P) | null | 2016-03-30 | AML 19 TRIAL | N | N | 240003307 | METHOTREXATE |
| 240008193 | 240013593 | 1.65 | null | Palliative (P) | 2016-06-25 | 2016-06-25 | VEDex | N | N | 240003350 | CHLVPP |
| 240008194 | 240013593 | 1.8 | 89.5 | Curative (C) | 2015-09-18 | 2015-09-21 | FCR | N | N | 240003350 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 240008195 | 240005023 | null | 103 | Not known (9) | 2018-03-26 | 2018-03-27 | RCEOP | null | N | 240003383 | FCR |
| 240008196 | 240010781 | 1.63 | 60.3 | Curative (C) | null | 2018-03-16 | IDELALISIB + RITUXIMAB | 01 | null | 240003415 | CISPLATIN + FLUOROURACIL |
| 240008197 | 240005024 | 1.78 | 43 | Curative (C) | 2013-08-13 | 2013-08-31 | PACLITAXEL | N | N | 240003545 | R-CHOEP |
| 240008198 | 240005025 | 1.52 | 45.3 | Palliative (P) | 2018-08-14 | 2018-08-14 | METHOTREXATE | N | Y | 240003557 | CVP |
| 240008199 | 240005025 | 1.73 | 75.3 | Palliative (P) | 2017-09-17 | 2017-09-19 | Etoposide oral | N | N | 240003557 | mEOC TRIAL |
| 240008200 | 240005026 | 1.75 | 38.3 | Curative (C) | 2016-01-13 | 2016-01-29 | CISPLATIN + GEMCITABINE | N | N | 240003610 | RUXOLITINIB |
| 240008201 | 240005027 | 1.56 | 79.6 | Disease modification (D) | 2014-05-28 | 2014-06-05 | IVA | 02 | N | 240003693 | CISPLATIN + FLUOROURACIL |
| 240008202 | 240005027 | 1.62 | null | Palliative (P) | 2014-10-12 | 2014-10-26 | CISPLATIN + ETOPOSIDE | N | N | 240003693 | ABVD |
| 240008203 | 240005028 | 1.68 | 79.8 | Curative (C) | 2014-10-20 | 2014-10-24 | Cytarabine + Idarubicin | Y | N | 240003725 | BORTEZOMIB + THALIDOMIDE |
| 240008204 | 240005028 | 1.8 | 63.65 | Disease modification (D) | 2016-08-08 | 2016-08-19 | ABVD | 02 | N | 240003725 | CVD |
| 240008205 | 240013594 | 1.85 | 62.1 | Curative (C) | 2017-01-28 | 2017-02-27 | Methotrexate intrathecal | N | N | 240003873 | FCR |
| 240008206 | 240013594 | 1.7 | 76 | Palliative (P) | 2018-04-05 | 2018-04-09 | EC | 02 | N | 240003873 | CETUXIMAB |
| 240008210 | 240005030 | 1.65 | 60.6 | Palliative (P) | 2014-04-08 | 2014-04-09 | Cytarabine Low Dose | N | N | 240004027 | BEVACIZUMAB |
| 240008211 | 240005031 | 1.65 | 81.9 | Palliative (P) | 2017-11-01 | 2017-11-02 | NHL 2003 Gp B COPADM 1 & 2 | N | N | 240004084 | CTD |
| 240008212 | 240005031 | 1.61 | 57 | Palliative (P) | 2018-10-19 | 2018-10-19 | Cytarabine Low Dose | 2 | N | 240004084 | CISPLATIN + TOPOTECAN |
| 240008213 | 240005031 | 1.73 | 58.3 | Curative (C) | null | 2015-02-17 | ABVD | 01 | N | 240004084 | BRENTUXIMAB |